A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Butobarbital
Dichlorvos
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Dichlorvos.
Butobarbital
Coumaphos
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Coumaphos.
Butobarbital
Capsaicin
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Capsaicin.
Butobarbital
Glycine betaine
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Glycine betaine.
Butobarbital
Aprotinin
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Aprotinin.
Butobarbital
Regramostim
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Regramostim.
Butobarbital
Phenserine
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Phenserine.
Butobarbital
Huperzine A
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Huperzine A.
Butobarbital
Thiotepa
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Thiotepa.
Butobarbital
1,10-Phenanthroline
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with 1,10-Phenanthroline.
Butobarbital
Bambuterol
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Bambuterol.
Butobarbital
Neostigmine
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Neostigmine.
Butobarbital
Ginkgo biloba
The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Ginkgo biloba.
Butobarbital
Cannabinol
The risk or severity of Tachycardia and drowsiness can be increased when Umeclidinium is combined with Cannabinol.
Butobarbital
Palmidrol
The risk or severity of Tachycardia and drowsiness can be increased when Umeclidinium is combined with Palmidrol.
Butobarbital
Nabiximols
The risk or severity of Tachycardia and drowsiness can be increased when Umeclidinium is combined with Nabiximols.
Butobarbital
WIN 55212-2
The risk or severity of Tachycardia and drowsiness can be increased when Umeclidinium is combined with WIN 55212-2.
Butobarbital
Surinabant
The risk or severity of Tachycardia and drowsiness can be increased when Umeclidinium is combined with Surinabant.
Butobarbital
Ibipinabant
The risk or severity of Tachycardia and drowsiness can be increased when Umeclidinium is combined with Ibipinabant.
Butobarbital
Ajulemic acid
The risk or severity of Tachycardia and drowsiness can be increased when Umeclidinium is combined with Ajulemic acid.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3